8-K: Profound Medical's TULSA Procedure Gains Spotlight at SIR 2026

Profound Medical Corp. announces its TULSA Procedure will be prominently featured in multiple presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting.

Summary

• Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced that its interventional MRI (iMRI) TULSA Procedure will be highlighted in several presentations at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto, ON, from April 11-15, 2026.
• The TULSA Procedure, performed using the TULSA-PRO system, is an incision-free, MRI-guided therapy for prostate cancer and benign prostatic hyperplasia (BPH).
• The procedure utilizes robotically controlled directional ultrasound to precisely heat prostate tissue to 55-57C, while protecting surrounding nerves and anatomy, with real-time MRI thermography for continuous visualization and autonomous temperature adjustment.
• Key benefits include no procedural blood loss, no overnight hospital stay, a quicker return to everyday life, and minimized side effects such as urinary incontinence and erectile dysfunction.
• Five oral presentations will feature TULSA-PRO in the 'Men's Health 1' session on April 12th, covering topics like prostate cancer at the extreme apex, recurrent prostate cancer, a systematic review and meta-analysis of outcomes, automated prostate segmentation, and initial perioperative outcomes from the Level 1 post-market CAPTAIN trial.
• Two additional presentations on the TULSA Procedure will occur on April 13th during a categorical course titled 'Prostate Interventions: TULSA and Beyond'.
• Profound also commercializes Sonalleve, an MRI-guided therapy for pain palliation of bone metastases, desmoid tumors, osteoid osteoma, uterine fibroids, and adenomyosis, and is exploring additional clinical applications.
• TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, as increased visibility and presentation of clinical data at a major scientific conference can significantly boost market awareness, physician adoption, and investor confidence in Profound Medical's TULSA Procedure.

Positives

• Significant visibility for the TULSA Procedure at a major scientific meeting (SIR 2026), enhancing market awareness and physician adoption.
• Multiple presentations by leading physicians and researchers, including a '2026 Featured Abstract' for automated prostate segmentation, validating the technology.
• Presentation of Level 1 post-market CAPTAIN trial data, comparing TULSA to robotic prostatectomy for intermediate-risk prostate cancer, which can drive clinical acceptance.
• Growing awareness and acceptance of TULSA's strong clinical profile and its potential to become a mainstream treatment modality for prostate disease.
• Highlighting patient benefits such as incision-free treatment, real-time MRI guidance, precision, minimal side effects, no blood loss, and faster recovery.
• Broad regulatory approvals for TULSA-PRO and Sonalleve across major global markets, indicating strong commercial potential.

Risks

• Risks inherent in the medical device industry.
• Challenges related to regulatory approvals for new and existing products.
• Uncertainties regarding reimbursement policies and coverage.
• Impact of broader economic factors on business operations and market demand.
• General risks associated with equity markets.
• Risks related to company growth and competitive pressures.
• Forward-looking events and circumstances may not occur as anticipated or at all, and actual results could differ materially due to known and unknown risk factors.

Future Outlook

Profound Medical expects to build on the growing awareness and acceptance of the TULSA Procedure's strong clinical profile and its potential to become a mainstream treatment modality. The company plans to highlight CAPTAIN trial data and showcase real-world physician experience throughout 2026. Additionally, Profound is exploring further clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Management Comments

• "Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed."
• "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing."
• "We look forward to building on that progress by highlighting CAPTAIN trial data and showcasing real-world physician experience throughout 2026."

Industry Context

StockSavvy.ai notes that the significant presence of Profound Medical's TULSA Procedure at the 2026 Society of Interventional Radiology Annual Scientific Meeting underscores the growing trend towards minimally invasive, image-guided therapies in prostate care. This aligns with broader industry shifts focusing on improved patient outcomes, reduced recovery times, and fewer side effects compared to traditional surgical or radiation treatments. The emphasis on real-time MRI guidance and AI-powered solutions positions Profound at the forefront of technological advancements in the medical device sector, potentially challenging established treatment modalities and increasing market adoption for advanced ablation techniques.

Stakeholder Impact

• Shareholders: Potential for increased investor confidence and share price appreciation due to enhanced visibility and validation of TULSA-PRO's clinical efficacy.
• Patients: Access to an advanced, incision-free prostate treatment option with minimized side effects, no blood loss, and faster recovery for prostate cancer and BPH.
• Physicians/Healthcare Providers: Increased awareness and understanding of the TULSA Procedure's capabilities, potentially leading to broader adoption and improved patient care strategies.
• Competitors: Increased competitive pressure in the prostate treatment market, particularly for traditional surgical and radiation therapies, as TULSA-PRO gains traction.

Next Steps

• Presentations at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting from April 11-15, 2026.
• Highlighting CAPTAIN trial data throughout 2026.
• Showcasing real-world physician experience throughout 2026.
• Exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Key Dates

Recommendation

The announcement of multiple presentations at a prestigious scientific meeting, including Level 1 trial data, provides significant validation and exposure for Profound Medical's TULSA Procedure. This increased visibility and clinical endorsement are crucial for driving adoption and market penetration, suggesting a positive trajectory for the company's growth and stock value.

Keywords

Profound Medical, TULSA-PRO, MRI-guided therapy, prostate cancer, BPH, benign prostatic hyperplasia, interventional radiology, medical device, ultrasound ablation, Sonalleve, cancer treatment, urology